BioStock Investor Meeting: Pharmiva presents

19 September 2022 - 08:27

At last week’s BioStock Investor Meeting, femtech company Pharmiva was first out to present. CEO Anna Linton talked about Pharmiva’s product against bacterial vaginosis, Vernivia, which was launched in Sweden at the end of 2021. Linton also elaborated on the company’s expansion strategy and the current rights issue that will support a global launch.

See the presentation at

This is a press release from BioStock - Connecting Innovation & Capital

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Pharmiva AB
Pharmiva is a medical technology company. It develops innovative antibiotic-free medical products in order to improve vaginal health....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More